| In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-α MK Connolly, AS Bedrosian, JMS Clair, AP Mitchell, J Ibrahim, A Stroud, ... The Journal of clinical investigation 119 (11), 3213-3225, 2009 | 346 | 2009 |
| Function and dynamics of PKD2 in Chlamydomonas reinhardtii flagella K Huang, DR Diener, A Mitchell, GJ Pazour, GB Witman, JL Rosenbaum The Journal of cell biology 179 (3), 501-514, 2007 | 218 | 2007 |
| Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review AP Mitchell, NU Trivedi, RL Gennarelli, S Chimonas, SM Tabatabai, ... Annals of internal medicine 174 (3), 353-361, 2021 | 188 | 2021 |
| Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver J Ibrahim, AH Nguyen, A Rehman, A Ochi, M Jamal, CS Graffeo, ... Gastroenterology 143 (4), 1061-1072, 2012 | 170 | 2012 |
| Financial relationships with industry among National Comprehensive Cancer Network guideline authors AP Mitchell, EM Basch, SB Dusetzina JAMA oncology 2 (12), 1628-1631, 2016 | 115 | 2016 |
| Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice AP Mitchell, MR Harrison, MS Walker, DJ George, AP Abernethy, ... Journal of oncology practice 11 (6), 491-497, 2015 | 79 | 2015 |
| Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States AP Mitchell, RJ Simpson BMC research notes 5, 1-6, 2012 | 63 | 2012 |
| Pharmaceutical industry payments and oncologists’ selection of targeted cancer therapies in medicare beneficiaries AP Mitchell, AN Winn, SB Dusetzina JAMA Internal Medicine 178 (6), 854-856, 2018 | 52 | 2018 |
| Evaluating the strength of the association between industry payments and prescribing practices in oncology AP Mitchell, AN Winn, JL Lund, SB Dusetzina The Oncologist 24 (5), 632-639, 2019 | 38 | 2019 |
| Association between reimbursement incentives and physician practice in oncology: a systematic review AP Mitchell, JS Rotter, E Patel, D Richardson, SB Wheeler, E Basch, ... JAMA oncology 5 (6), 893-899, 2019 | 36 | 2019 |
| Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial EF Gillespie, JC Yang, NJ Mathis, CB Marine, C White, Z Zhang, ... Journal of Clinical Oncology 42 (1), 38-46, 2024 | 27 | 2024 |
| Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform T Torgerson, C Wayant, L Cosgrove, EA Akl, J Checketts, R Dal Re, J Gill, ... BMJ evidence-based medicine 27 (1), 46-54, 2022 | 26 | 2022 |
| Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics A Mitchell, B Muluneh, R Patel, E Basch Journal of Oncology Pharmacy Practice 24 (6), 424-432, 2018 | 23 | 2018 |
| Deferred systemic therapy in patients with metastatic renal cell carcinoma AP Mitchell, BR Hirsch, MR Harrison, AP Abernethy, DJ George Clinical Genitourinary Cancer 13 (3), e159-e166, 2015 | 18 | 2015 |
| Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis AP Mitchell, BR Hirsch, AP Abernethy Trials 15, 1-5, 2014 | 18 | 2014 |
| Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study AP Mitchell, SB Dusetzina, AM Meza, NU Trivedi, PB Bach, AN Winn bmj 383, 2023 | 16 | 2023 |
| Cost savings and increased access with ultra-low-dose immunotherapy AP Mitchell, DA Goldstein Journal of Clinical Oncology 41 (2), 170, 2023 | 16 | 2023 |
| Clinical trial subjects compared to" real world" patients: Generalizability of renal cell carcinoma trials. AP Mitchell, MR Harrison, DJ George, AP Abernethy, MS Walker, ... Journal of Clinical Oncology 32 (15_suppl), 6510-6510, 2014 | 16 | 2014 |
| Isolation of intraflagellar transport trains C Mencarelli, A Mitchell, R Leoncini, J Rosenbaum, P Lupetti Cytoskeleton 70 (8), 439-452, 2013 | 16 | 2013 |
| Real-world use of bone-modifying agents in metastatic castration-sensitive prostate cancer AP Mitchell, A Mishra Meza, KS Panageas, A Lipitz-Snyderman, PB Bach, ... JNCI: Journal of the National Cancer Institute 114 (3), 419-426, 2022 | 14 | 2022 |
Peter B. BachMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
